Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Director | June 19, 2020 | June 22, 2020 |
| Kinnate Biopharma Inc.KNTE · Entity 92187 | Director | December 02, 2020 | December 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Crinetics Pharmaceuticals, Inc.
Report date June 19, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.23 · Expires 2030-06-18 | Direct | 12,500 |
Reported balance
After 2020-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-19 · Grant · Acquired 12,500 · Balance 12,500 F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Kinnate Biopharma Inc.
Report date December 02, 2020 · Filed December 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,615,826 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,615,826 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2030-03-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-02 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Option vests and becomes exercisable over time at the following rate: 170,885 of the total number of shares subject to the Option vested and became exercisable on August 20, 2020, and thereafter 1/20th of the remaining shares shall vest each month in equal installments on the first day of each month. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-02 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The Option vests and becomes exercisable over time at the following rate: 1/24th of the total number of shares subject to the Option shall vest monthly in equal installments over two years commencing on the one-month anniversary of August 1, 2020, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests and becomes exercisable over time at the following rate: 170,885 of the total number of shares subject to the Option vested and became exercisable on August 20, 2020, and thereafter 1/20th of the remaining shares shall vest each month in equal installments on the first day of each month.
F2: The Option vests and becomes exercisable over time at the following rate: 1/24th of the total number of shares subject to the Option shall vest monthly in equal installments over two years commencing on the one-month anniversary of August 1, 2020, the Vesting Commencement Date, and each month thereafter on the same day of the month as the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2020 Filed Jun 22, 2020 20:22 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-20-038172 · doc4.xml · derivative · entry 1 Kaldor Stephen W · CIK 0001507502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 20:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $23.24 | $0.00 |
DisclosureSEC source: 0001209191-19-038896 · doc4.xml · derivative · entry 1 Kaldor Stephen W · CIK 0001507502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-20 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.